Stacey A. Cohen, MD

Articles

Patient Profile: A 52-Year-Old Woman With Colorectal Cancer

April 1st 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

Evolution of MRD Testing in Colorectal Cancer

April 1st 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

Practical Considerations in MRD Testing in CRC

March 25th 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

Colorectal Cancer: MRD Testing in the Community Setting

March 25th 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

Testing for MRD in Colorectal Cancer

March 18th 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

MRD Testing Platforms in Colorectal Cancer

March 18th 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

When is MRD Testing Performed in Colorectal Cancer Treatment?

March 11th 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

Treating Colorectal Cancer: Overview of MRD Testing and ctDNA

March 11th 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

July 26th 2023

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

July 19th 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

July 19th 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Assessing HER2 Expression in Metastatic Colorectal Cancer

July 12th 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer

July 12th 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Colorectal Cancer: Evolving Role of ctDNA Testing in Practice

June 28th 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer

June 21st 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Biomarker Testing in Metastatic Colorectal Cancer

June 21st 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Dr. Cohen on the Timing of ctDNA Testing in Resected Stage I-III CRC

January 31st 2023

Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.